Curated News
By: NewsRamp Editorial Staff
June 08, 2026

Optimi Health Advances Ibogaine Initiative with GMP-Grade Production Plans

View History of this news story on GitHub
Original Source

TLDR

  • Optimi Health secures naturally derived ibogaine, positioning itself to capture emerging demand in psychedelic therapy markets.
  • Optimi will develop standardized 50 mg and 100 mg ibogaine capsules at its GMP facility using validated manufacturing processes.
  • Optimi's ibogaine initiative aims to advance mental health therapies, supported by growing public funding for psychedelic research.
  • Ibogaine, derived from an African shrub, is being developed by Optimi for potential therapeutic use in addiction treatment.

Impact - Why it Matters

This news matters because it signals a significant step forward in the development of ibogaine as a regulated therapeutic for mental health conditions like addiction and PTSD. With Optimi Health leveraging its existing GMP infrastructure and Canadian regulatory licenses, the company is poised to supply high-quality ibogaine for clinical research and potential therapeutic use. The growing public funding for psychedelic therapies, such as the $50 million program in Texas, indicates increasing acceptance and demand. For investors and patients, this development could accelerate access to ibogaine-based treatments and open new avenues in psychedelic medicine.

Summary

Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI, FSE: 8BN) has announced significant progress on its Ibogaine Initiative, securing naturally derived ibogaine in both hydrochloride and freebase forms from two independent sources. The company expects to begin developing finished ibogaine drug products this summer at its GMP-certified manufacturing facility in British Columbia, Canada. Plans include producing standardized 50 mg and 100 mg encapsulated dosage formats designed for research and regulated access programs. This development leverages the same GMP infrastructure that Optimi currently uses to produce psilocybin and MDMA products, positioning the company to meet growing demand for high-quality ibogaine in clinical research and potential therapeutic applications.

The announcement comes amid a surge of interest in ibogaine research and expanding public funding for psychedelic therapies, including a recently launched $50 million program in Texas. Optimi's management believes that Canada's regulatory framework and the company's existing Health Canada licenses provide a strategic advantage to support increasing demand for GMP-grade ibogaine. The development program will encompass formulation, manufacturing validation, analytical testing, and packaging processes, ensuring that the final products meet rigorous quality standards for research and therapeutic use.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities. The company supplies active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, visit optimi.net. This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Optimi Health Advances Ibogaine Initiative with GMP-Grade Production Plans

blockchain registration record for this content.